Company Continues to Make Progress on Planned Separation of Eye Health Business
Announces Leadership Team of Bausch + Lomb
Now Operates in Five Reportable Segments
Reaffirmed 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges
Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company or we ) today announced its first-quarter 2021 financial results. Bausch Health entered 2021 with strong momentum as our recovery from the COVID-19 pandemic continues. Our business is generating strong cash flow, many of our leading products have increased market share in key markets, and we are advancing our pipeline, said Joseph C. Papa, chairman and CEO, Bausch Health.
Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting
News provided by
Share this article
Share this article
PRINCETON, N.J., May 4, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (
Fluorescent
Synthetic
Hypericin) study, presented confirmatory data at the Society for Investigative Dermatology (SID) Virtual Meeting, held May 3-8, 2021. The presentation was selected to be shown during a Concurrent Mini-Symposium for Patient-Targeted Research. The presented data demonstrated the abil
IRRAS AB publishes Interim Report for the period January to March 2021
Meaningful Commercial Acceleration Seen Globally
News provided by
Share this article
STOCKHOLM, May 4, 2021 /PRNewswire/ During Q1, the global installed base for IRRAS products increased; the total number of IRRAflow systems increased from 73 to 84 and Hummingbird systems grew from 5 to 9. An increase in the number of systems shipped is important, but it is more critical to convert evaluations into revenue-generating commercial customers. During the quarter, two influential US comprehensive stroke centers, Buffalo General Medical Center and West Virginia University, placed commercial disposable stocking orders for IRRAflow. The contracts signed by these customers more than doubled the number of commercial IRRAflow control units (from 9 to 19) and will generate recurring revenue as usage continues.
Share this article
Share this article
ORLANDO, Fla., May 4, 2021 /PRNewswire/ Cabenuva (cabotegravir/rilpivrine), the first and only once-monthly complete injectable treatment is available through AllianceRx Walgreens Prime for adults living with human immunodeficiency virus type 1 (HIV-1). Manufactured for ViiV Healthcare by GlaxoSmithKline, Cabenuva provides an alternative to patients who relied on a daily oral treatment regimen.
HIV is a virus that attacks the body s immune system. If not treated, it can lead to acquired immunodeficiency syndrome (AIDS).
1 HIV-1 is the predominant type of HIV worldwide, making up 95 percent of all HIV cases worldwide.
2 Cabenuva a complete regimen for the treatment of HIV-1 infection in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Zymergen Hires Former Apple Executive and Ford Motor Leader as Chief Manufacturing Officer
Seasoned manufacturing executive brings experience managing multi-billion dollar consumer product lines to scale biofacturing platform for commercial markets
News provided by
Share this article
EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ Biofacturing leader
Zymergen today announced Aindrea Campbell is joining the company as Chief Manufacturing Officer, developing and leading Zymergen s global manufacturing and supply chain activities. Aindrea has a proven track record of running multi-billion dollar product lines, and her experience across manufacturing, procurement and supply chain will be instrumental in scaling our production capabilities, said Josh Hoffman, Zymergen CEO.